Best Drug Delivery Companies in Israel
The 40 best Drug Delivery companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: PolyPid.
- Rapid Drug Delivery Solution: Enhance Pharmacy’s Services With Mobile
- Multiple sclerosis, diabetes and migraine are therapy areas where alte
Ranked: Best Drug Delivery companies in Israel
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PolyPid Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API) 60Funding top 18%Moat top 29%Patents top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 29% Patentstop 38% Techtop 39% Innovationtop 46% Growthtop 48% Markettop 50% Globaltop 50% Newsbottom 40% Funding: Raised $96.7M across 10 rounds · 10 rounds over 14 yrs (0.7/yr) Moat: Editorial + unicorn rating 6/10 · IP moat: 138 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $97M | 14 mo ago | Public | — | 2008 | DrupalPHPSalesforce+20 | 138 patents Antimicrobial and anticancer pharmaceutical compositions for surgical infections and tumors | — |
| 2 | SteadyMed Therapeutic drug-device combinations | $44M | 112 mo ago | Acquired | — | 2005 | — | 94 patents Portable and patch-based drug infusion pump systems for treprostinil delivery and pain reduction | — |
| 3 | Regentis Biomaterials Biodegradable hydrogels for tissue regeneration. | $25M | 63 mo ago | Public | — | 2004 | — | 79 patents Solvent‑free protein‑polymer conjugate formulations for medical and biotech applications | 2 expansions |
| 4 | Oramed Developer of oral reformulations to treat various health conditions | $23M | 77 mo ago | Public | — | 2006 | WordPressMySQLPHP+22 | 102 patents Oral delivery technologies for peptide therapeutics targeting diabetes and metabolic diseases | — |
| 5 | Aposense Molecular imaging and drug development based on apoptosis-based technology | $16M | 195 mo ago | Public | — | 1996 | — | 116 patents Transmembrane drug and peptide delivery technologies for intracellular therapeutic delivery | — |
| 6 | NanoPass Technologies Microneedles-based device for intradermal delivery 37Innovation top 39%Patents top 39%Funding top 42%Moat top 45% All 8 signals ▾Innovationtop 39% Patentstop 39% Fundingtop 42% Moattop 45% Techtop 48% Talentbottom 49% Globalbottom 43% Marketbottom 30% Innovation: 75 patents (top 36% of patent-holders) Patents: 75 patents matched (strict assignee match) · Latest publication 2016 rank vs industry peers · Fliar Intelligence Index 37/100 | $15M | 25 mo ago | Series C | Daniel Levitats Chief Executive Officer | 2000 | WordPressMySQLPHP+25 | 74 patents Microneedle-enabled intradermal drug delivery systems and associated manufacturing methods. | 1 partnership |
| 7 | Formulex Developer of cannabinoid drug products | $1M | 211 mo ago | Series A | Galia Krayz CEO | 2001 | — | — | — |
| 8 | Omeq Medical Developer of a sensor-based epidural placement system for epidural injections | $700K | 157 mo ago | Seed | — | 2011 | — | — | — |
| 9 | LipoMedix Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer | $639K | 81 mo ago | Funding Raised | Alberto Gabizon Founder & CEO | 2011 | — | — | — |
Top 12 Drug Delivery companies in Israel
#1
Public · Petah Tikva, Central District · founded 2008 · 69 employees$96.7Mraised▾
PolyPid has developed a technology platform (PLEX-Polymer-Lipid Encapsulation matriX) that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). Its technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. It allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. Its pipeline includes D-PLEXantibiotic drug reservoir designed to be implanted during surgery to prevent or treat surgical site infections (SSIs)), Bonypid-1000 (an antibiotic designed for bone related infections applications) and Bonypid-500 (an antibiotic eluting bone graft substitute intended to fill, augment or reconstruct periodontal or oral/maxillofacial defects while protecting from infections)
- Jun 2025Post IPO$26.7M
- Dec 2024Post IPO$14.5M
- Aug 2024Post IPO$14.2M
- Jan 2024Post IPO$35M
#2
Series C · Ness Ziona, Center District · founded 2000 · 16 employees$14.9Mraised▾
NanoPass Technologies develops intradermal delivery solutions for vaccines and immunotherapies. They have developed, MicronJet needle, a single use microneedles-based device for intradermal delivery. It can be used with any standard syringe to painlessly deliver any liquid substance directly into the skin. The MicronJet can be used with any standard syringe to inject drugs, proteins and vaccines approved for that delivery route.
- Jul 2024Series C$6M
- Apr 2016Series C—
- Jul 2012Series B—
- Feb 2007Series A$6.5M
#3
Public · Or Akiva, Haifa District · founded 2004 · 3 employees$25Mraised▾
Regentis Biomaterials is a tissue repair company focused on developing and commercializing an hydrogel platform for the repair of damaged tissue. It is focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin is the regenerative hydrogel platform for all product development. GelrinC is a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage.
- May 2021Grant (prize money)$61K
- Jun 2019Grant (prize money)$2.4M
- Jan 2019Grant (prize money)$698.3K
- Feb 2016Series D$15M
#4
Acquired · Rehovot, Central District · founded 2005 · 24 employees$44.2Mraised▾
SteadyMed is a medical-device company which has developed technology for delivering high volume (>2 ml) small molecule or biologic drugs. Its stated primary focus is specialty pharma product (drug-device combination) development. Licensing of their technology is a secondary business focus. The application areas targeted currently are pulmonary arterial hypertension and at-home analgesia. The products are yet to receive FDA approval. The company went public in March 2015.
- Apr 2017Post IPO$30M
- Aug 2016Post IPO$32M
- Jan 2015Series C$12.2M
- Jun 2014Series C$19.6M
#5
Public · Jerusalem, Jerusalem District · founded 2006 · 17 employees$22.6Mraised▾
Developer of oral reformulations to treat various health conditions. Its proprietary platform POD(Protein Oral Delivery) technology protects proteins from an enzymatic breakdown in the GI tract while increasing bioabsorption across the intestinal wall. The product pipeline includes ORMD-0801 for type-2 and type-1 diabetes. In addition, the company has another candidate that is an oral formulation Exenatide, a glucagon-like peptide-1 analog that stimulates insulin secretion.
- Mar 2020Grant (prize money)$55.3K
- Dec 2019Grant (prize money)$55.1K
- Jul 2018Post IPO$18.1M
- Jan 2013Post IPO$76.4K
#6
Public · Petah Tikva, Central District · founded 1996 · 12 employees$16.3Mraised▾
Aposense has developed a proprietary platform technology, based on membrane-related cellular processes, and their recruitment to improve patient care. The Aposense Technology focuses on the electrical potential map of cell membrane, for the purposes of gene delivery, drug delivery, molecular imaging and optimization of drug pharmacokinetic profile. Based on analysis of the electrical potential map of phospholipid membranes, Aposense aims to build a proprietary Molecular Nano-Motors (MNM), capable of moving within the core of the cell membrane helping to improve drug delivery and performance.
#7
Funding Raised · Jerusalem, Jerusalem District · founded 2011$638.8Kraised▾
Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer. The company's lead drug mitomycin-C, a chemotherapeutic agent, and its delivery in liposomes called Promitil – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) for colon cancer.
- Nov 2019Grant (prize money)$55K
- Jul 2019Grant (prize money)$56.4K
- May 2016Grant (prize money)$527.3K
#8
Series A · Rehovot, Central District · founded 2001$1.4Mraised▾
Formulex is a developer of cannabinoid drug products. The company is a developer of nano-technology based drug delivery and formulations. The products developed are Solumer, OMEXA and NASAX.
- Feb 2009Series A$1.4M
#9
Seed · Ramat Gan, Tel Aviv District · founded 2011 · 4 employees$700Kraised▾
Developer of a sensor-based epidural placement system for epidural injections. The product is used for reducing labor pain in pregnant ladies, surgical procedures by anesthesiologists, in the treatment of obstetrics, acute and chronic pain.
#10
Funding Raised · Jerusalem, Jerusalem District · founded 2005 · 8 employees$80.6Kraised▾
Developer of liposome-based nano drugs for cancer, autoimmune diseases, sclerosis, and post-operative pain. The proprietary platform allows for the remote drug loading into nanoliposomes and enables controlled release of the drugs at the targeted site allowing for enhanced permeability and retention (EPR). The lead candidate LC-400 in human trials for post-operative pain. Its other programs include LC-100 for breast & ovarian cancer, LC-200 for neuritis, sclerosis, RA lupus, and LC-300 for solid tumors.
- Apr 2020Grant (prize money)$80.6K
#11
Deadpooled · Ramat Gan, Tel Aviv District · founded 2010—raised▾
Vecoy Nanomedicines is a nano-biopharmaceutical company focussed on the application of nanomedicine technologies to the complex issues of viral diseases. Its technology is based on the use of a tailor-made virus-traps that mimic human host cells to serve as a Virus-Decoy which has the capability to entrap the virus particles before the cellular infection takes place. It claims that its technology even addresses the virus resistance to treatment and toxicity effects, and is designed to be resistance and toxicity free.
- May 2013Grant (prize money)—
#12
Acqui-Hired · Misgav, Northern District · founded 2010—raised▾
Operator of a medical device company. The company provides a inhalation platform to deliver small molecule drugs such as corticosteroids, beta agonists and larger molecules to treat respiratory diseases.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in Israel
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 195 Israel-affiliated papers.
- Tel Aviv University34
- Hebrew University of Jerusalem25
- Ben-Gurion University of the Negev24
- Technion – Israel Institute of Technology23
- Weizmann Institute of Science23
- Computational biology5→24
- Chemical space1→8
- Pharmacology1→7
- Drug development1→6
- Pharmacophore2→5
- Computational biology2→12
- Pharmacology2→4
- Computational biology1→4
Where drug discovery is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.